Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/1999
10/21/1999WO1999052938A2 Identification of chemical active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway in parasites
10/21/1999WO1999052935A1 Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide
10/21/1999WO1999052932A1 Fatty acid derivatives of bile acids and bile acid derivatives
10/21/1999WO1999052929A1 Nucleic acid sequences and proteins associated with aging
10/21/1999WO1999052927A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
10/21/1999WO1999052926A1 Regulated target expression for screening
10/21/1999WO1999052925A1 Programmed cell death and caspase-12
10/21/1999WO1999052910A1 Bicyclic hydroxamic acid derivatives
10/21/1999WO1999052907A1 Azabicyclic 5ht1 receptor ligands
10/21/1999WO1999052903A1 Prodrugs of benzofuranylmethyl carbamate nk1 antagonists
10/21/1999WO1999052898A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors
10/21/1999WO1999052896A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999WO1999052890A1 Chromanone and thiochromanone derivatives
10/21/1999WO1999052889A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
10/21/1999WO1999052870A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
10/21/1999WO1999052869A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes
10/21/1999WO1999052868A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999WO1999052862A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
10/21/1999WO1999052858A2 Lipids
10/21/1999WO1999052848A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999WO1999052847A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999WO1999052552A1 T cell inhibitory receptor compositions and uses thereof
10/21/1999WO1999052534A1 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
10/21/1999WO1999052525A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/21/1999WO1999052524A1 Use of cannabinoids as anti-inflammatory agents
10/21/1999WO1999052516A2 Acylpeptide protease inhibitors to enhance cognitive function
10/21/1999WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999WO1999052493A2 Compounds that inhibit the binding of integrins to their receptors
10/21/1999WO1999052463A1 Needleless administration of polynucleotide formulations
10/21/1999WO1999046379A3 Human receptor proteins; related reagents and methods
10/21/1999WO1999046254A3 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis
10/21/1999WO1999042577A3 Biotin-binding receptor molecules
10/21/1999WO1999040925A3 Hapten-modified tumor cell membranes and their use
10/21/1999WO1999040061A3 Novel dihydroxyhexanoic acid derivatives
10/21/1999WO1999038501A9 Method of regulating glucose metabolism, and reagents related thereto
10/21/1999WO1999030738A3 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/21/1999WO1999030157A9 Neuropilins in methods for diagnosis and prognosis of cancer
10/21/1999WO1999026927A3 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
10/21/1999WO1999015654A3 Tie receptor tyrosine kinase ligand homologues
10/21/1999WO1998020932A3 Conditioning for allogeneic stem cell transplantation
10/21/1999DE19916896A1 Particles for chelating metal ions, useful in cosmetic, pharmaceutical and food products and products for treating liquids, especially water
10/21/1999DE19818614A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817461A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817459A1 New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19816857A1 Novel adenosine antagonists useful in treatment of e.g. neurodegenerative, pulmonary, renal and cardiovascular disorders
10/21/1999DE19816624A1 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel New substituted indolinones, their preparation and their use as medicaments
10/21/1999CA2328878A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/21/1999CA2328725A1 T cell inhibitory receptor compositions and uses thereof
10/21/1999CA2328360A1 Improvements in or relating to protease inhibitors
10/21/1999CA2328250A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999CA2328245A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999CA2328211A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999CA2328180A1 Needleless administration of polynucleotide formulations
10/21/1999CA2328157A1 Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway
10/21/1999CA2327782A1 Azabicyclic 5ht1 receptor ligands
10/21/1999CA2327516A1 Programmed cell death and caspase-12
10/21/1999CA2327477A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
10/21/1999CA2327431A1 Pharmaceutical composition
10/21/1999CA2326665A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
10/21/1999CA2325824A1 Tao protein kinases and methods of use therefor
10/21/1999CA2325629A1 Crystalline forms of 1s-[1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9-[[(1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino[1, 2-a][1,2] diazepin- 1-carboxamide
10/21/1999CA2325602A1 Regulated target expression for screening
10/21/1999CA2325599A1 Novel nep ii membrane metalloprotease and its use for screening inhibitors useful in therapy
10/21/1999CA2325559A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
10/21/1999CA2325332A1 Therapeutic agent for ngf
10/21/1999CA2325010A1 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
10/21/1999CA2323934A1 Nucleic acid sequences and proteins associated with aging
10/20/1999EP0950661A1 Substituted tricyclics useful in sPLA2 induced diseases
10/20/1999EP0950657A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors
10/20/1999EP0950417A2 Treatment of skeletal disorders
10/20/1999EP0950406A2 Remedy for CAG repeat expansion diseases
10/20/1999EP0950103A2 Survivin, a protein that inhibits cellular apoptosis, and its modulation
10/20/1999EP0950100A1 Keratinocyte growth factor-2 (kgf-2 or fibroblast growth factor-12, fgf-12)
10/20/1999EP0950060A1 Antisense inhibition of human adhesion molecules
10/20/1999EP0950053A1 Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
10/20/1999EP0950047A1 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
10/20/1999EP0949931A1 Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
10/20/1999EP0949922A1 Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors
10/20/1999EP0949921A1 Thrombin inhibitors
10/20/1999EP0832078B1 N-hydroxyureas as antiinflammatory agents
10/20/1999EP0788476B1 Stilbene derivatives useful as cyclooxygenase-2 inhibitors
10/20/1999EP0783318A4 Inhibitors of farnesyl-protein transferase
10/20/1999EP0740655B1 Metalloproteinase inhibitors
10/20/1999CN1232505A Nucleic acid sequences that encode cell growth regulatory protein and uses thereof
10/20/1999CN1232503A Tumor necrosis factor related ligand
10/20/1999CN1232497A AGE-1 polypeptides and related molecules and methods
10/20/1999CN1232457A 1,4-heterocyclic metalloprotease inhibitors
10/20/1999CN1232451A Substd. cyclic amine metalloprotease inhibitors
10/20/1999CN1232447A Hydroxamic acid derivs.
10/20/1999CN1232400A Anti-stress drugs and functional foods having anti-stress effects
10/20/1999CN1232399A Inhibitors of cysteine protease
10/20/1999CN1232028A Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
10/20/1999CN1232025A Pyrrolidine and piperidine derivatives
10/20/1999CN1231844A Silkworm chrysalis contg. compound amino acid oral liquid and preparing process thereof
10/20/1999CN1045778C Novel chemical compounds having P.DE-IV inhibition activity
10/20/1999CN1045777C Tetracyclic derivs. process of preparation and use
10/20/1999CN1045772C Polyazacycloalkanes as dichelants
10/20/1999CN1045770C Method for preparation of 1-biphenylmethyl imidazole derivs.
10/20/1999CN1045769C Process for preparing sulfurous derivs. of imidazole
10/20/1999CN1045768C Angiotension II antagonists compounds, preparing method and use thereof
1 ... 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 ... 1564